Drug manufacturers Carter-Wallace, Inc., and the U.S. Food and Drug Administration (FDA) have advised physicians to immediately stop prescribing the antiepileptic drug, Felbatol, because it has been associated with 10 cases of aplastic anemia. Physicians are advised to take all Felbatol patients off the drug, unless abrupt withdrawal might pose a greater risk, Carter-Wallace officials stated. Aplastic anemia occurred in patients who had been taking Felbatol for two- and-a-half to six months. Two patients among 10 reported aplastic anemia cases have died.
This content is only available via PDF.
Copyright © 1994 by the American Academy of Pediatrics